Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXC 001 for scarring after breast scar revision
NCT01037413Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2009
- Primary completion
- Apr 2010
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of EXC 001 in Hypertrophic Scar (HS), sponsored by Pfizer. Started Dec 2009; status: completed.
02
Drugs
EXC 001
03
Conditions
Hypertrophic Scar (HS)
Beyond the preview
Go deeper on NCT01037413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01037413.